2834 – Page 111 – China Stock Advice

BSPM [Biostar Pharmaceuticals,] S-8: FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT

[FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 including zip code) (Full title of the plan) Ronghua Wang President and Chief Executive Officer No. 588 Shiji Xi Avenue] [Biostar Pharmaceuticals, Inc. 2011 Stock Option Compensation Plan This Biostar Pharmaceuticals, Inc. 2011 Stock Option Compensation Plan Plan 1. Definitions. (a) Board " (b) Code " (c) Committee Rule 16b-3 Exchange Act " (d) Company " (e) Exchange Act " (f) Fair Market Value " (g) Grant " (h) Grant Agreement " (i) Maryland Securities Rules " (j) Option Optionee] [[Cozen O’Connor Letterhead] August 16, 2012 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 Re: Registration Statement on Form S-8 Very truly yours, EX-5 3 ex5-1.htm] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 of Biostar Pharmaceuticals, Inc. of our report dated March 27, 2012 relating to the consolidation financial statements, which appears in the Annual Report on Form 10-K of Biostar Pharmaceuticals,]

By info| 2016-03-03T11:50:18+00:00 August 17th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 2012-08-17, 2834, BSPM, PHARMACEUTICAL PREPARATIONS, S-8|0 Comments

BSPM [Biostar Pharmaceuticals,] S-8: FORMS-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF

[FORMS-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Maryland (State or other jurisdiction oforporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China 712046luding zipde) (Full title of the plan) Ronghua Wang President and Chief Executive Officer] [Biostar Pharmaceuticals, 2011 Stock Optionmpensation Plan This Biostar Pharmaceuticals, 2011 Stock Optionmpensation Plan Plan 1. Definitions. (a) Board " (b)de " (c)mmittee Rule 16b-3 Exchange Act " (d)mpany " (e) Exchange Act " (f) Fair Market Value " (g) Grant " (h) Grantreement] [[Cozen OConnor Letterhead] August 16, 2012 Biostar Pharmaceuticals, No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China 712046 Re: Registration Statement on Form S-8 Very truly yours, ex5-1.htm 3 EX-5] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to theorporation by reference in the Registration Statement on Form S-8of Biostar Pharmaceuticals, of our reportted March 27, 2012 relating to thensolidation financial statements, which appears in the Annual Report on Form 10-K of Biostar Pharmaceuticals, for the]

By info| 2016-02-07T15:43:26+00:00 August 17th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 2012-08-17, 2834, BSPM, PHARMACEUTICAL PREPARATIONS, S-8|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By info| 2016-03-03T11:52:28+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 10-Q, 2012-08-14, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x June 30, 2012

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2012 President and Chief Executive Officer EX-32.1 4 cphi10qex321063012.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2012 (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322063012.htm]

By info| 2016-03-03T17:43:09+00:00 August 14th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 10-Q, 2012-08-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q: (Original Filing)

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weibing Lu, Chief Executive Officer] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Bing Mei, Chief Financial Officer]

By info| 2016-03-01T04:35:33+00:00 August 14th, 2012|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 10-Q, 2012-08-14, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x June 30, 2012

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By info| 2016-03-03T11:53:19+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-Q, 2012-08-14, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-Q:

[] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weibing Lu, Chief Executive Officer] [(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Bing Mei, Chief Financial Officer]

By info| 2016-03-01T04:36:37+00:00 August 14th, 2012|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 10-Q, 2012-08-14, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Delaware 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2012 President and Chief Executive Officer EX-32.1 4 cphi10qex321063012.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: August 14, 2012 (principal financial officer and principal accounting officer) EX-32.2 5 cphi10qex322063012.htm]

By info| 2016-03-03T17:42:08+00:00 August 14th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 10-Q, 2012-08-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x June 30, 2012 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Zack Pan Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 5 EX-32.2]

By info| 2016-02-07T15:45:04+00:00 August 14th, 2012|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 10-Q, 2012-08-14, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS 3 4 2

[Form 6-K TABLE OF CONTENTS 3 4 2]

By info| 2016-04-02T17:37:07+00:00 August 14th, 2012|Categories: Chinese Stocks, Webplus ver, WX|Tags: 0001403132, 2012-08-14, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, WX|0 Comments